ClinicalTrials.gg
CompletedNCT02163902Updated Feb 17, 2020Results posted

Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101

A Phase 3 interventional study of ATX-101 and Placebo in Submental Fat and Healthy, sponsored by Kythera Biopharmaceuticals. Completed at 15 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-17.

Sponsored by Kythera Biopharmaceuticals (part of AbbVie) · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
224
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The investigation of the long-term safety and maintenance of efficacy of ATX-101 in reduction of submental fat.

Read the detailed description

No study medication is administered in this study.

02

Conditions studied

  • Submental Fat
  • Healthy
03

In context

Lead sponsor

Kythera Biopharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.

First submitted before Kythera Biopharmaceuticals became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Any participant who completed follow-up visits at 12 and 24 weeks after the last dose in one of the two predecessor studies
  2. Willingness to comply with the schedule and procedures of this study.
  3. Signed form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Participants who have had any treatment or condition (e.g., pregnancy or metabolic disease, which may lead to unstable weight) that may affect assessment of safety or efficacy since enrollment in the predecessor study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    ATX-101

    Participants treated with ATX-101 in previous studies ATX-101-11-22 and ATX-101-11-23.

    Drug: ATX-101

  • Placebo comparator
    Placebo

    Participants treated with placebo in previous studies ATX-101-11-22 and ATX-101-11-23.

    Drug: Placebo

Interventions

  • Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events

  • DrugPlacebo

    Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

    Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment

Secondary outcomes

  1. Percentage of Participants Maintaining CR-SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis

    Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment.

  2. Percentage of Participants Maintaining PR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

    Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment

  3. Percentage of Participants Maintaining PR-SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

    Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment

  4. Percentage of Participants Maintaining Composite SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

    Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment

  5. Percentage of Participants Maintaining Composite SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

    The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

    Time frame: From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment

07

Results

Posted Feb 17, 2020

Participant flow

The objective of this non-treatment, double-blind, placebo-controlled follow-up study was to evaluate the long-term efficacy and safety of subcutaneous (SC) injections of deoxycholic acid (ATX-101) in the submental area. No treatment was administered in this study.

Participant flow — Overall Study
MilestoneATX-101 (Deoxycholic Acid) InjectionPlacebo
Started113111
Completed10298
Not completed1113
Withdrew: Subject's request34
Withdrew: Lost to follow-up67
Withdrew: Administrative decision22

Outcome measures

PrimaryPercentage of Participants Maintaining CR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

Time frame:
From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining CR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Visit 1 (Year 1) Percentage86.4 (79.2 to 93.5)56.8 (42.2 to 71.5)
Visit 2 (Year 2) Percentage90.6 (84.4 to 96.8)73.8 (60.5 to 87.1)
Visit 3 (Year 3) Percentage82.4 (74.2 to 90.5)65.0 (50.2 to 79.8)
SecondaryPercentage of Participants Maintaining CR-SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis

Time frame:
From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment.
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining CR-SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Visit 1 (Year 1) Percentage75.0 (61.6 to 88.4)18.2 (0.0 to 41.0)
Visit 2 (Year 2) Percentage72.5 (58.7 to 86.3)33.3 (2.5 to 64.1)
Visit 3 (Year 3) Percentage65.8 (50.7 to 80.9)33.3 (2.5 to 64.1)
SecondaryPercentage of Participants Maintaining PR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

Time frame:
From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining PR-SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Visit 1 (Year 1) Percentage95.5 (91.1 to 99.8)76.4 (65.1 to 87.6)
Visit 2 (Year 2) Percentage87.8 (81.0 to 94.5)83.0 (72.9 to 93.1)
Visit 3 (Year 3) Percentage77.0 (68.2 to 85.9)75.0 (62.8 to 87.2)
SecondaryPercentage of Participants Maintaining PR-SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

Time frame:
From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining PR-SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Visit 1 (Year 1) Percentage59.0 (43.5 to 74.4)63.6 (35.2 to 92.1)
Visit 2 (Year 2) Percentage57.5 (42.2 to 72.8)60.0 (29.6 to 90.4)
Visit 3 (Year 3) Percentage59.5 (43.6 to 75.3)70.0 (41.6 to 98.4)
SecondaryPercentage of Participants Maintaining Composite SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

Time frame:
From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Composite SMFRS 1-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 1-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Visit 1 (Year 1) Percentage86.8 (79.2 to 94.4)44.8 (26.7 to 62.9)
Visit 2 (Year 2) Percentage85.1 (77.0 to 93.2)64.3 (46.5 to 82.0)
Visit 3 (Year 3) Percentage72.6 (62.4 to 82.8)46.2 (27.0 to 65.3)
SecondaryPercentage of Participants Maintaining Composite SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits

The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst). The participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst). Non-responders at LTFU baseline in each treatment group (including placebo) were not included in the analysis.

Time frame:
From 12 weeks after last treatment (in the predecessor study) to up to 36 months after last treatment
Reported as:
Number · percentage of participants
Percentage of Participants Maintaining Composite SMFRS 2-Grade Response During 3 Years of Follow up, i.e. % of Participants Who Were CR-SMFRS and PR-SMFRS 2-Grade Responders at Both Long-term LTFU Baseline and at Subsequent LTFU Visits
percentage of participantsATX-101 (Deoxycholic Acid) InjectionPlacebo
Visit 1 (Year 1) Percentage41.2 (17.8 to 64.6)0.0 (NA to NA)
Visit 2 (Year 2) Percentage43.8 (19.4 to 68.1)0.0 (NA to NA)
Visit 3 (Year 3) Percentage50.0 (23.8 to 76.2)50.0 (0.0 to 100.0)

Adverse events

Collected over From the first exposure to study drug in predecessor study to up to 36 months after last treatment in predecessor study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ATX-101 (Deoxycholic Acid) Injection0/113 (0%)5/113 (4.4%)0/113 (0%)
Placebo0/111 (0%)1/111 (0.9%)0/111 (0%)
Most frequent serious events
Most frequent serious events
EventATX-101 (Deoxycholic Acid) InjectionPlacebo
DiverticulitisGastrointestinal disorders2/1130/111
Breast cancer in situNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/961/95
Breast reconstructionSurgical and medical procedures1/960/95
Ovarian cancer recurrentReproductive system and breast disorders1/960/95
Small cell lung cancer stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1130/111

Baseline characteristics

Age, Continuous
Age, Continuous(years)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Mean51.0 ± 8.2250.1 ± 9.0050.6 ± 8.61
Age, Customized
Age, Customized(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
≤ 30 years347
> 30 to ≤ 50 years5249101
> 50 years5858116
< 50 years474794
Sex: Female, Male
Sex: Female, Male(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Female9695191
Male171633
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Hispanic or Latino332558
Not Hispanic or Latino8086166
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
American Indian or Alaska Native011
Asian415
Native Hawaiian or Other Pacific Islander101
Black or African American12719
White96101197
More than one race011
Unknown or Not Reported000
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
Mean29.283 ± 4.493428.836 ± 4.009929.062 ± 4.2570
Fitzpatrick Score
Fitzpatrick Score(Participants)ATX-101 (Deoxycholic Acid) InjectionPlaceboTotal
I448
II303969
III333669
IV352055
V9918
VI235
08

Study locations

15 sites
  • Dermatology Cosmetic Laser Medical Associates of La Jolla
    San Diego, California 92121, United States
  • AboutSkin Dermatology and DermSurgery, PC
    Englewood, Colorado 80113, United States
  • Dermatology Research Institute
    Coral Gables, Florida 33146, United States
  • Stephan Baker MD PA
    Coral Gables, Florida 33146, United States
  • Baumann Cosmetic and Research Center
    Miami, Florida 33137, United States
  • Kenneth R. Beer, MD, PA
    West Palm Beach, Florida 33401, United States
  • Altman Dermatology Associates
    Arlington Hts, Illinois 60005, United States
  • DeNova Research
    Chicago, Illinois 60611, United States
  • DuPage Medical Group, Dermatology Institute
    Naperville, Illinois 60563, United States
  • Callender Center for Clinical Research
    Glendale, Maryland 20769, United States
  • Aesthetics, Skin Care, Dermatologic Surgery
    Rockville, Maryland 20850, United States
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
  • Research Across America
    Plano, Texas 75093, United States
  • Shannon Humphrey, MD
    Vancouver, V5Z 4E1, Canada
  • Carruthers Dermatology Centre Inc.
    Vancouver, V5Z4E1, Canada
09

References and documents

Publications

  • Humphrey S, Cohen JL, Bhatia AC, Green LJ, Green JB, Bowen B. Improvements in Submental Contour up to 3 Years After ATX-101: Efficacy and Safety Follow-Up of the Phase 3 REFINE Trials. Aesthet Surg J. 2021 Oct 15;41(11):NP1532-NP1539. doi: 10.1093/asj/sjab100. PubMed 33617632 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jan 2016 and a completion of Aug 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2020, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2014
First posted
Jun 16, 2014
Start
Dec 2013
Primary completionActual
Jan 2016
CompletionActual
Aug 2016
Results first posted
Feb 17, 2020
Last update
Feb 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02163902
Responsible party
Sponsor
First posted
Jun 16, 2014
Start date
Dec 2013
Primary completion
Jan 2016
Completion
Aug 2016
Results posted
Feb 17, 2020
Last update
Feb 17, 2020

Study contacts

Frederick Beddingfield, III, MD, PhD
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: APIM-containing Peptide ATX-101

Start the discussion